Get the Stockscreener App
0.7504
3.15%
-0.0244
After Hours:
.80
0.0496
+6.61%
Lexaria Bioscience Corp stock is traded at $0.7504, with a volume of 252.71K.
It is down -3.15% in the last 24 hours and up +4.44% over the past month.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$0.7748
Open:
$0.7659
24h Volume:
252.71K
Relative Volume:
0.48
Market Cap:
$18.68M
Revenue:
$522.00K
Net Income/Loss:
$-10.80M
P/E Ratio:
-1.3064
EPS:
-0.5744
Net Cash Flow:
$-8.78M
1W Performance:
+3.50%
1M Performance:
+4.44%
6M Performance:
-28.53%
1Y Performance:
-58.24%
1-Day Range:
$0.75
$0.84
1-Week Range:
$0.6997
$0.84
52-Week Range:
$0.46
$1.85
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.7504 | 19.28M | 522.00K | -10.80M | -8.78M | -0.5744 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Stock Recap: Will Lexaria Bioscience Corp Equity Warrant face regulatory challenges2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Lexaria's Robust Patent Portfolio Continues to Grow - Investing News Network
Lexaria Bolsters Global Patent Portfolio With New GLP-1 and Cardiometabolic IP - TipRanks
LEXX Advances with New Patents for Hypertension, Epilepsy, and D - GuruFocus
Lexaria receives 5 patents including 2 for diabetes treatment By Investing.com - Investing.com India
Lexaria receives 5 patents including 2 for diabetes treatment - Investing.com
Five new patents extend Lexaria's diabetes and epilepsy claims into 2044 - Stock Titan
FOMO Trade: How does Lexaria Bioscience Corp correlate with Nasdaq2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
Aug Intraday: How does Lexaria Bioscience Corp correlate with Nasdaq2026 Market Mood & Daily Entry Point Alerts - baoquankhu1.vn
Moving Averages: Will Lexaria Bioscience Corp Equity Warrant stock go up in YEARShare Buyback & Daily Entry Point Alerts - baoquankhu1.vn
Lexaria pursues oral GLP-1 drug delivery partnerships By Investing.com - Investing.com Australia
If You Invested $1,000 in Lexaria Bioscience Corp (LEXX) - Stock Titan
Lexaria Targets Booming GLP-1 Market With Enhanced Oral Drug Platform - TipRanks
Lexaria pursues oral GLP-1 drug delivery partnerships - Investing.com
Lexaria Bioscience Corp.: Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - FinanzNachrichten.de
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - standard-journal.com
Weight-loss pills over shots? Lexaria says pharma talks are underway - Stock Titan
Aug Decliners: Can Lexaria Bioscience Corp expand into new markets2026 Pullback Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Published on: 2026-03-22 08:08:07 - baoquankhu1.vn
Is Lexaria Bioscience Corp exposed to political risk2026 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
100,000 Lexaria (LEXX) shares gifted back to the company - Stock Titan
Update Recap: Is Lexaria Bioscience Corp benefiting from interest rate changesPortfolio Return Report & Capital Protection Trade Alerts - baoquankhu1.vn
Volume Recap: Is Lexaria Bioscience Corp a strong candidate for buy and hold2026 Drop Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
Market Rankings: Can Lexaria Bioscience Corp Equity Warrant sustain earnings growthTrade Risk Assessment & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Lexaria launches 2026 research program for drug delivery tech - Investing.com Nigeria
Buybacks Report: Will Lexaria Bioscience Corp Equity Warrant outperform tech stocksJuly 2025 Sector Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Buybacks Report: Is Lexaria Bioscience Corp Equity Warrant currently under institutional pressureAnalyst Upgrade & Weekly Breakout Stock Alerts - baoquankhu1.vn
Aug Wrap: Can Lexaria Bioscience Corp Equity Warrant sustain earnings growth2025 Market Sentiment & Stock Market Timing Techniques - baoquankhu1.vn
Lexaria Bioscience files to sell 2.76M shares of common stock for holders - MSN
Lexaria launches 2026 research program for drug delivery tech By Investing.com - Investing.com Australia
Lexaria Announces New R&D Plans for 2026 - Investing News Network
Lexaria Launches 2026 R&D Push to Advance GLP-1 and Cannabidiol Drug Delivery - TipRanks
Lexaria Bioscience Corp Announces New Research and Development Program - marketscreener.com
LEXX Initiates 2026 R&D Program to Enhance Pharma Innovations - GuruFocus
Biotech tests new oral GLP-1 formulas against Wegovy tablets - Stock Titan
Update Recap: Will Smith Douglas Homes Corp benefit from rate cuts2025 Big Picture & Long Hold Capital Preservation Plans - baoquankhu1.vn
Is Lexaria Bioscience Corp. exposed to currency risksMarket Performance Recap & Technical Pattern Alert System - mfd.ru
Lexaria Bioscience: Improving Oral Weight-Loss Drug Tolerability - The Globe and Mail
Aug Wrap: Is Lexaria Bioscience Corp a strong candidate for buy and holdEarnings Recap Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Lexaria Bioscience: Oral Drug Delivery Technology Targets Next-Gen Weight Loss Market - The Globe and Mail
LEXX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aug Intraday: Can Lexaria Bioscience Corp expand into new marketsJuly 2025 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
US Market Wrap: What are the risks of holding Hanover Bancorp IncMarket Growth Summary & Safe Capital Allocation Plans - baoquankhu1.vn
Update Report: Can Lexaria Bioscience Corp Equity Warrant sustain earnings growth2025 Dividend Review & Low Risk Investment Opportunities - baoquankhu1.vn
Published on: 2026-02-20 23:25:19 - baoquankhu1.vn
Will Lexaria Bioscience Corp. Equity Warrant stock go up in YEARJuly 2025 Selloffs & Entry Point Confirmation Signals - mfd.ru
Published on: 2026-02-20 04:22:15 - baoquankhu1.vn
Aug Intraday: Is Lexaria Bioscience Corp exposed to currency risksJuly 2025 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Aug Action: Will NHICU outperform tech stocksDip Buying & Verified Short-Term Trading Plans - baoquankhu1.vn
Is Lexaria Bioscience Corp. likely to announce a buyback2025 Support & Resistance & Entry Point Strategy Guides - mfd.ru
How Lexaria Bioscience Corp. Equity Warrant stock performs in interest rate cyclesQuarterly Earnings Summary & AI Optimized Trade Strategies - mfd.ru
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):